The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study

Background The purpose of this study was to assess the reproducibility of the previously described T2-fluid attenuated inversion recovery (FLAIR) mismatch sign as a specific imaging marker in non-enhancing isocitrate dehydrogenase (IDH) mutant, 1p/19q non-codeleted lower-grade glioma (LGG), encompassing both diffuse and anaplastic astrocytoma. Methods MR scans (n = 154) from 3 separate databases with genotyped LGG were evaluated by 2 independent reviewers to assess (i) presence/absence of "T2-FLAIR mismatch" sign and (ii) presence/absence of homogeneous signal on T2-weighted images. Interrater agreement with Cohen's kappa (κ) was calculated, as well as diagnostic test performance of the T2-FLAIR mismatch sign to identify IDH-mutant astrocytoma. Results There was substantial interrater agreement for the T2-FLAIR mismatch sign [κ = 0.75 (0.64-0.87)], but only fair agreement for T2 homogeneity [κ = 0.38 (0.25-0.52)]. The T2-FLAIR mismatch sign was present in 38 cases (25%) and had a positive predictive value of 100%, negative predictive value of 68%, a sensitivity of 51%, and a specificity of 100%. Conclusions With a robust interrater agreement, our study confirms that among non-enhancing LGG the T2-FLAIR mismatch sign represents a highly specific imaging marker for IDH-mutant astrocytoma. This non-invasive marker may enable a more informed patient counsel and can aid in the treatment decision processes in a significant proportion of patients presenting with non-enhancing, LGG-like lesions.

[1]  Armin Giese,et al.  Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma , 2018, Neuro-oncology.

[2]  M. J. van den Bent,et al.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.

[3]  Karra A. Jones,et al.  Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status , 2017, Journal of Neuro-Oncology.

[4]  W. Dinjens,et al.  Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.

[5]  Sohil H. Patel,et al.  T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project , 2017, Clinical Cancer Research.

[6]  M. J. van den Bent,et al.  Imaging Correlates of Adult Glioma Genotypes. , 2017, Radiology.

[7]  Susan M. Chang,et al.  A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics , 2017, Neuro-oncology.

[8]  M. J. van den Bent,et al.  Does early resection of presumed low-grade glioma improve survival? A clinical perspective , 2017, Journal of Neuro-Oncology.

[9]  Susan M. Chang,et al.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide , 2016, Neuro-oncology.

[10]  M. J. van den Bent,et al.  Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. , 2016, The Journal of molecular diagnostics : JMD.

[11]  T. Tominaga,et al.  Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion , 2016, Journal of Neuro-Oncology.

[12]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[13]  Pieter Wesseling,et al.  Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.

[14]  Andrei I Holodny,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[15]  S. Heiland,et al.  IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma , 2015, Scientific Reports.

[16]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[17]  Gabriele Schackert,et al.  Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.

[18]  S. Plevritis,et al.  Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features. , 2015, Radiology.

[19]  Neema Jamshidi,et al.  Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. , 2013, Radiology.

[20]  G. Reifenberger,et al.  Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.

[21]  Geirmund Unsgård,et al.  Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. , 2012, JAMA.

[22]  B. Tress,et al.  MR imaging characteristics of protoplasmic astrocytomas , 2011, Neuroradiology.

[23]  R Grant,et al.  Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force , 2010, European journal of neurology.

[24]  Luc Taillandier,et al.  Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. , 2009, Neuro-oncology.

[25]  K. Hoang-Xuan,et al.  Chromosome 1p loss evaluation in anaplastic oligodendrogliomas , 2008, Neuropathology : official journal of the Japanese Society of Neuropathology.

[26]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[27]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[28]  J. Rutka,et al.  Fluid-attenuated Inversion Recovery Ring Sign as a Marker of Dysembryoplastic Neuroepithelial Tumors , 2007, Journal of computer assisted tomography.

[29]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[30]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.